

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Cancer</b>				
Lung cancer	ATG7 autophagy related 7 homolog (ATG7)	<p>Mouse studies suggest acute inhibition of autophagy could be useful for treating lung cancer. In a mouse model of lung cancer, inhibition of autophagy via conditional deletion of <i>Atg7</i> for five weeks decreased tumor volume and burden compared with no alteration. Normal mice with conditional deletion of <i>Atg7</i> lasting more than two months showed susceptibility to infection, neurodegeneration, liver damage and fasting-induced fatal hypoglycemia, suggesting autophagy inhibition might only have a favorable therapeutic profile in acute regimens. Ongoing work includes determining how systemic autophagy deficiency compromises tumor metabolism and growth.</p> <p><b>SciBX 7(27); doi:10.1038/scibx.2014.793</b>  <b>Published online July 17, 2014</b></p>	<p>Covered by issued and filed patents; available for licensing from Rutgers University  <b>Contact:</b> Shan Wan, Rutgers University, New Brunswick, N.J.                      e-mail: <a href="mailto:shanwan@otc.rutgers.edu">shanwan@otc.rutgers.edu</a></p>	<p>Karsli-Uzunbas, G. <i>et al. Cancer Discov.</i>; published online May 29, 2014; doi:10.1158/2159-8290.CD-14-0363  <b>Contact:</b> Eileen White, Rutgers University, New Brunswick, N.J.                      e-mail: <a href="mailto:epwhite@cinj.rutgers.edu">epwhite@cinj.rutgers.edu</a></p>